Last reviewed · How we verify
Clopradone — Competitive Intelligence Brief
phase 2
Selective Serotonin Reuptake Inhibitors
5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Clopradone (ETOPERIDONE). Clopradone works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clopradone TARGET | ETOPERIDONE | phase 2 | Selective Serotonin Reuptake Inhibitors | 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Selective Serotonin Reuptake Inhibitors class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clopradone CI watch — RSS
- Clopradone CI watch — Atom
- Clopradone CI watch — JSON
- Clopradone alone — RSS
- Whole Selective Serotonin Reuptake Inhibitors class — RSS
Cite this brief
Drug Landscape (2026). Clopradone — Competitive Intelligence Brief. https://druglandscape.com/ci/etoperidone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing